Tag: IPR
-
Apple v. Squires: Federal Circuit Upholds NHK-Fintiv Against APA Rulemaking Challenge
On February 13, 2026, the Federal Circuit issued its long-awaited decision in Apple Inc. v. Squires, No. 2024-1864 (Fed. Cir. Feb. 13, 2026), affirming that the USPTO Director’s NHK-Fintiv framework governing discretionary denials of IPR institution is a “general statement of policy” exempt from notice-and-comment rulemaking under 5 U.S.C. § 553(b). The opinion closes what…
-
Ethanol Boosting Systems v. Ford: Federal Circuit Enforces PTAB Institution Finality and Issue Preservation
The Federal Circuit’s December 23, 2025 decision in Ethanol Boosting Systems, LLC v. Ford Motor Company delivers a comprehensive reminder of three recurring themes in modern PTAB litigation: the near-impenetrable bar to reviewing institution decisions, the limits of importing district court claim constructions into inter partes review, and the evidentiary deference accorded to the Board’s…
-
IBM v. Zillow: Prior Art Must Disclose What the Patent Claim Actually Requires
On December 9, 2025, the Federal Circuit issued a precedential decision in International Business Machines Corp. v. Zillow Group, Inc., affirming a split Patent Trial and Appeal Board decision that invalidated some claims of IBM’s single sign-on patent while preserving others. The opinion offers a careful, almost tutorial-like, explanation of how far the Board may…
-
In re Gesture Technology: IPR Estoppel Stops at the PTAB Door, Not Ex Parte Reexamination
The Federal Circuit’s December 1, 2025 decision in In re Gesture Technology Partners, LLC, Appeal No. 2025-1075, delivers a clean and consequential message on two recurring pressure points in post-grant practice: the reach of inter partes review (IPR) estoppel under 35 U.S.C. § 315(e)(1), and the Patent Office’s authority to continue adjudicating validity in ex…
-
In re Motorola Solutions: Mandamus Cannot Bypass the § 314(d) Bar on IPR Institution Review
On November 6, 2025, the U.S. Court of Appeals for the Federal Circuit denied Motorola Solutions, Inc.’s petition for a writ of mandamus seeking to overturn the USPTO’s decision to deinstitute eight inter partes reviews involving Stellar, LLC’s patents. The order in In re Motorola Solutions, Inc., No. 25-134 (Fed. Cir. Nov. 6, 2025), reinforces…
-
Centripetal Networks v. Palo Alto Networks: When Recusal Fails but Secondary Considerations Revive an IPR
On October 22, 2025, the Federal Circuit issued a mixed but consequential decision in Centripetal Networks, LLC v. Palo Alto Networks, Inc., vacating the Patent Trial and Appeal Board’s final written decision and remanding for further proceedings. While the court firmly rejected Centripetal’s sweeping recusal and due process challenges, it nonetheless concluded that the Board…
-
Inland Diamond Prods v. Cherry Optical: PTAB Fact Findings Do Not Preclude District Court Validity Challenges
On October 15, 2025, the Federal Circuit vacated and remanded a summary judgment of invalidity in Inland Diamond Products Co. v. Cherry Optical Inc., No. 24-1106, holding that the district court improperly applied issue preclusion based on prior PTAB inter partes review decisions. The ruling reinforces a principle the court has been developing with increasing…
-
Causam v. ecobee: Federal Circuit Addresses PTAB Standing, Due Process, and Claim Construction
On the same day the Federal Circuit dismissed Causam’s ITC appeal as moot, it issued the companion decision that explains why the appeal became moot in the first place. In Causam Enterprises, Inc. v. ecobee Technologies ULC, No. 24-1958 (Fed. Cir. Oct. 15, 2025), the court affirmed the Patent Trial and Appeal Board’s final written…
-
US Inventor v. USPTO: Standing Doctrine Closes the Courthouse Door on AIA Rulemaking Challenges
The Federal Circuit’s decision in US Inventor, Inc. v. United States Patent and Trademark Office, No. 2024-1396 (Fed. Cir. Oct. 3, 2025), reinforces a familiar but increasingly consequential theme in administrative patent law: access to judicial review turns first, and often last, on Article III standing. Even when a dispute implicates the scope of the…
-
Bayer Pharma v. Mylan Pharmaceuticals: When “Clinically Proven Effective” Cannot Rescue an Anticipated Treatment Method
The Federal Circuit’s September 23, 2025 decision in Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc., No. 23-2434, delivers a sharp reminder that post-hoc validation, even in the form of successful clinical trial results, does not automatically translate into patentability. The opinion clarifies the limits of method-of-treatment claims that attempt to rely on clinical proof language…